Determinants of improved left ventricular function after thrombolytic therapy in acute myocardial infarction  by Sheehan, Florence H.
JACC Vol. 9. NO.4
April 1987:937-44
SEMINAR ON THROMBOLYSIS IN MYOCARDIAL INFARCTION-IV
John H. K. Vogel, MD, FACC, Guest Editor
Determinants of Improved Left Ventricular Function After
Thrombolytic Therapy in Acute Myocardial Infarction*
FLORENCE H. SHEEHAN, MD
Seattle. Washington
937
Many studies have been performed to evaluate the ef-
ficacy of thrombolytic therapy in achieving reperfusion,
salvaging myocardium and enhancing survival. This re-
view discusses the concordance between the results of
these clinical studies and the observations made in ex-
perimental animals of the effect of reperfusion on the
recovery of left ventricular function. The evaluation of
functional recovery is affected by the timing of the mea-
surement and the sensitivity of the method for detecting
regional abnormalities. In addition, the underlying coro-
nary anatomy also determines outcome, so that infarct
location, collateral circulation and the degree of coro-
nary obstruction merit consideration.
Since DeWood et al. (1) demonstrated the incidence of
coronary thrombosis and the safety of performing cardiac
catheterization in patients during acute myocardial infarc-
tion, there has been intense interest in thrombolytic therapy.
Most studies have focused on measuring the coronary re-
perfusion rate achieved by various agents and dosage reg-
imens. The underlying hypothesis is that reperfusion will
salvage myocardium and thereby reduce mortality. This hy-
pothesis is based on the observations made in studies of
reperfusion and infarct size reduction in experimental ani-
mals, but has not yet been verified in humans. However,
recent studies have demonstrated a beneficial effect of
thrombolytic therapy and reperfusion on survival after myo-
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Two factors are of paramount importance in deter-
mining the amount of myocardium salvaged, the recov-
ery of left ventricular function and the reduction in mor-
tality. These factors are: the time delay until reperfusion
is achieved and the adequacy of the coronary reftow.
The close agreement between studies measuring the ef-
fect of reperfusion on left ventricular function and stud-
ies with mortality as the end point provides indirect
evidence that enhancement of survival in patients treated
with thrombolytic agents is mediated by recovery of ven-
tricular function.
(J Am Coli Cardiol1987;9:937-44)
cardial infarction in certain patient subgroups. In retrospect,
the identification of these subgroups was foreseen by certain
experimental and clinical studies of the effect of reperfusion
in salvaging myocardium. Therefore, the present report will
review the experimental and clinical studies of myocardial
salvage after reperfusion from the viewpoint of their con-
cordance with the results of clinical trials testing survival
after thrombolytic therapy. Because salvage of left ventric-
ular function is the link between achievement of reperfusion
and enhancement of survival, identification of the factors
influencing recovery of ventricular function after throm-
bolytic therapy will form the framework for this discussion.
Measurement of Myocardial Salvage
The term myocardial salvage refers to a reduction in
infarct size from that anticipated if no intervention were
applied (2). In experimental animals, it is possible to mea-
sure infarct size directly from the mass of infarcted tissue,
with the assistance of tetrazolium stains of slices of the left
ventricle, and compare it with the mass of myocardium at
risk of infarction, determined by perfusing the beds of the
occluded and nonoccluded arteries with differently colored
0735-1097/87/$3.50
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stains (3,4). In humans, measurements are much less pre-
cise, even using quantitative analysis of thallium-201 scin-
tigrams (5,6). Estimation of infarct size from creatine kinase
(CK) release (7) or changes on the electrocardiogram (8) is
even more indirect.
The term myocardial salvage is also applied to the re-
covery of left ventricular function after a therapeutic inter-
vention in patients with infarction. Although the severity of
left ventricular dysfunction correlates with infarct size, the
relation is not close enough to permit an accurate assessment
of the mass of the infarcted myocardium (9). This is partly
because function may also be depressed in normally per-
fused myocardium adjacent to an acutely ischemic region
(10). Also, the gradual resolution of wall motion abnor-
malities with time results in a constantly shifting relation
with infarct size (II). Furthermore, ventricular function and
infarct size are not linearly related (12,13). Finally, infarc-
tion may also cause asynchronous contraction, an abnor-
mality that may be missed when evaluating function at end-
systole alone (14,15).
Thus measurement of left ventricular function provides
only an approximation of the mass of infarcted myocardium.
However, the appearance of clinical cardiac decompensation
correlates with the level of left ventricular function and
depends only indirectly on infarct size (16,17). Therefore,
it is more clinically relevant to assess myocardial salvage
by measuring the function of the viable myocardium than
the mass of the infarct.
When Should Left Ventricular
Function Be Measured?
After reperfusion of an occluded coronary artery in the
dog, there is a delay before contractile function returns to
normal (18). This delay occurs even after a 5 minute oc-
clusion, which is too brief to induce necrosis (19). Recovery
of function is more delayed after more prolonged occlusion
1.5
(18,20). Four to 7 days are required for recovery after a I
hour coronary occlusion; up to 4 weeks are required for
function to reach a plateau after 3 hour or permanent oc-
clusions (20,21). Even after rest function has peaked, the
ability of reperfused myocardium to respond to stress may
not recover until weeks later (20). The dysfunction of this
viable but' 'stunned" myocardium is attributed to disruption
of oxidative metabolism (22,23).
As a result, the salvage achieved by thrombolytic therapy
may be underestimated if left ventricular function is mea-
sured early after myocardial infarction, before recovery is
complete. Thus, no change in ejection fraction or regional
wall motion is seen immediately after reperfusion in most
(24-26) but not all (27) studies. Indeed, measurement of
left ventricular function during the first 24 hours after acute
infarction is so variable, as a result of I) the shifting hemo-
dynamic status, or 2) changes in perfusion due to sponta-
neous reperfusion or opening of collateral channels, or both,
that it would be difficult to demonstrate an improvement
(28,29).
Serial studies have not been performed in humans to
determine when left ventricular function reaches maximal
recovery after thrombolytic therapy. However, experimental
data suggest that measurements made earlier than 2 weeks
after infarction will overestimate dysfunction in patients
who undergo reperfusion later than 2 hours after the onset
of infarction or who fail to achieve reperfusion because their
recovery occurs more slowly, if at all, than if reperfusion
is achieved earlier.
Importance of Measuring Regional Left
Ventricular Function
In almost all experimental studies, the effect of coronary
artery occlusion and reperfusion on ventricular function was
evaluated within the ischemic region by measuring segment
length changes using sonomicrometers or strain gauges. It
*
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Figure 1. Change in wall motionand ejection fraction
after intracoronary streptokinase. Patientswithoptimal
reperfusion were sent for coronary artery bypass sur-
gery (+CABG); although motion in the infarct region
improved significantly, the ejection fraction change was
small because hyperkinesia in the opposite wall de-
creased concurrently. Patients with partial reperfusion
werenot sent to surgery (STREPTOKINASE ALONE);
the ejection fraction reflected the marked decrease in
hyperkinesia in the noninfarct region, rather than the
small improvement in the infarct region. In patients
without reperfusion or with rethrombosis, motion in
both walls decreased. and so did the ejection fraction.
(Adapted with permission from Sheehan FR et at
[33].)
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has long been recognized (30) that dysfunction of nonin-
volved regions reduces the accuracy with which the ejection
fraction indicates the severity of hypokinesia in the infarct
site. This problem is heightened by the unpredictable se-
verity and indeed the heterogeneity of the dysfunction in
the noninfarct region, which has ranged from hyperkinesia
to hypokinesia in experimental studies (31,32).
Significance of changes in ejection fraction. Never-
theless, there has been a tendency in clinical studies to
measure global ventricular performance from the ejection
fraction, even though acute compensatory hyperkinesia in
the noninfarcted region may develop in humans. Because
of this acute hyperkinesia, which usually subsequently sub-
sides, the ejection fraction has proved to be an unreliable
and insensitive measure of either the severity of hypokinesia
in the infarct region or the effect of therapeutic interventions
in salvaging function (33-35). The ejection fraction change
may not only underestimate recovery of regional function
in the infarct site after reperfusion (Fig. I), but also over-
estimate recovery if reperfusion benefits function in both
the infarct and noninfarct regions (36-38). Because of this
variable response of the noninfarct region. measurement of
the ejection fraction has usually yielded less significant, or
even insignificant, responses to reperfusion compared with
wall motion analysis (33,34.39). Thus. the inclusion of
regional wall motion analysis in clinical trials of throm-
bolytic therapy or of other interventions in ischemic heart
disease is useful for determining whether the observed ejec-
tion fraction changes accurately represent the effect of ther-
apy on function in the region of interest.
How is Outcome Related to the Acute
Severity of Ventricular Dysfunction?
It was recognized very early (40) that contraction ceases
within seconds after coronary artery occlusion and is often
replaced by paradoxic motion due to passive bulging of the
ischemic segment. Subsequent studies (41,42) demonstrated
that such akinetic or dyskinetic segments can recover con-
tractility even if reperfused as late as 3 hours after coronary
occlusion. However Lavallee et al. (20) found that after 2
I hour of ischemia, regions of the myocardium with severe
ventricular dysfunction were less likely to recover fully after
reperfusion than were regions with mild hypokinesia.
In patients with reperfusion, the greatest improvement in
ejection fraction occurs in those who had a depressed ejec-
tion fraction «45%) acutely (39,43). Similarly, the change
in wall motion after reperfusion correlates significantly with
the acute severity of regional dysfunction such that the great-
est improvement occurs among patients who had akinesia
or dyskinesia acutely (44). These data can be interpreted on
two levels. Simplistically. reperfusion results in recovery
of normal function; therefore. only a small improvement
will occur in patients with mild or moderate hypokinesia
acutely because greater improvement would result in hy-
perkinesia. More importantly. the data suggest that patients
with severely depressed ventricular function acutely have
the potential to achieve near-normal contraction if reper-
fusion is achieved early.
Reperfusion in cardiogenic shock and in anterior in-
farction. Indeed, clinical studies of the effect of throm-
bolytic therapy on survival support this conclusion, For
example. data from the registry of the Society for Cardiac
Angiography (45) showed that the in-hospital mortality rate
among patients in cardiogenic shock was lower in those who
achieved coronary reperfusion versus those who did not
(42.1 versus 84.0%, n = 45. P < 0.001). Furthermore.
although anterior infarcts are larger than inferior infarcts
and produce more extensive left ventricular dysfunction, it
is in patients with anterior infarction that reperfusion reduces
in-hospital and long-term mortality (46). Thus, it is for the
patient with the most severely compromised ventricular
function that thrombolytic therapy offers the greatest po-
tential benefit. The advisability of thrombolytic therapy for
patients with inferior infarction needs to be evaluated in this
light.
Influence of Pretreatment Coronary Anatomy
on Recovery of Ventricular Function
The status of the coronary circulation before thrombolytic
therapy has been repeatedly shown to be an important de-
terminant of the severity of ventricular dysfunction during
the acute infarction and of the magnitude of functional re-
covery. Three factors are involved: the location of the in-
farct-related coronary lesion, the presence of collateral ves-
sels and the presence of total or subtotal occlusion in the
infarct-related artery.
Left anterior descending versus right coronary artery
occlusion. The left anterior descending coronary artery sup-
plies more than half of the left ventricle in humans. the
right coronary artery only 21 % (47). Therefore. the mag-
nitude of left ventricular dysfunction is greater after anterior
wall infarction, because of the larger infarct size (48). The
location of the stenosis along the infarct artery is a significant
determinant of left ventricular function in left anterior de-
scending artery-related infarction with a more distal occlu-
sion producing less severe hypokinesia. This is not true for
right coronary artery-related infarction, perhaps because only
the posterior descending branch of this artery supplies the
left ventricle (49).
Collateral circulation. Collateral circulation to the in-
farct artery can be induced in the dog by gradual coronary
artery occlusion. The presence of collateral vessels reduces
infarct size after complete coronary occlusion (4). However,
in humans the incidence of collateral circulation at the time
of acute infarction is generally small (6 to 16%). The es-
timates vary by I) whether all or only "well developed"
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occiusion of the infarct artery (58); 2) the ejection fraction
decreased significantly in patients with unsuccessful reper-
fusion, except in those protected by collateral vessels or
subtotal occlusion(59); and 3) theejection fraction increased
in patients in whomCK release peakedearly after infarction,
presumably because of spontaneous reperfusion, but not in
patients with slow release (60).
MINIMUM DIAMETER OF STENOSIS. MM
Figure 3. Effect ofsevere residualcoronary stenosisonfunctional
recoveryafter thrombolytic therapy. Change inhypokinesia in the
infarct site, measured using thecenterline method and expressed
in terms of SD from normal, is plotted on the y axis. Stenosis
severity is plotted on the x axis in terms of the minimal diameter
of the stenosis. Patients in whom the residual minimal diameter
was ::;0.4 mm had significantly less functional recovery than pa-
tients with less severe residual stenosis . (Reproduced with per-
mission from Sheehan FH . et al. [44].)
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collateral vessels are counted, and 2) whenangiography was
performed relative to the onset of infarction, because col-
lateral vessels develop rapidly after infarction (50,51). When
present, collateral vessels exertaprotective effect in relation
to left ventricular function and prognosis (52,53).
Total versus subtotal occlusion. Incomplete coronary
occlusion is even mote protective; as indicated by the higher
ejection fraction in patients with this finding than in patients
with collateral vessels to a totally occluded artery. This
suggests that retrograde flow by way of collateral vessels is
less adequate than restrictedanterogradeflow (54). Because
the incidence of total coronary occlusion diminishes with
time after Infarction (I), patients presentingwith incomplete
coronary occlusion may have undergone spontaneous re-
perfusion of a previously occluded artery before the time
of angiography. Alternatively, it is theoreticallypossible for
infarction to occur under stressful conditions in the presence
of a critieal coronary artery stenosis. This has been dem-
onstrated in a dog model with an isoproterenol infusion as
the stress andcoronary constriction severeenough to prevent
reactive hyperemia but allow normal flow at rest (55). The
mechanism may be transient occlusion by platelet thrombi
(56) .
By either mechanism, the presence of incomplete coro-
nary occlusion before treatment is a natural model of very
early reperfusiori . This may explain the better baseline left
ventricular function in such patients (44) and their sponta-
neous improvement even without thrombolytic therapy (57).
The advantage of having incomplete or subtotal occlusion
is further supported by the following indirect evidence: I)
thallium perfusion defect size was most reduced after re-
perfusion achieved by intracoronary streptokinase in the
subset of patientswitheithercollateralcirculationor subtotal
Figure 2. Minimal Coronary cross-sectional areas inpatients with
coronary lesions that rethrombosed versus those with lesions that
remained patent. Rethrotnbosis occurred in 7 of 12 patients with
areas<0.4 mm?versus0 of 12 withareas >0.4 mrrr' (p < 0.005).
(Reprinted with permission from Harrison DG, et al. [641 .)
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Role of residual stenosis. Early investigators of throm-
bolytic therapy recognized that intracoronary streptokinase
therapy leaves a significant residual stenosis in the infarct
artery (61). Attempts to relate the severity of this residual
stenosis to the patient's clinical outcome failed (62), prob-
ably because of the inaccuracy of visual estimates of stenosis
severity (63). When quantitative analysis of the severity of
the residual stenosis was perforrried, the risk of reocclusion
could be shown to increase significantly when the minimal
area of the lumen was less thim 0.4 mm?(Fig. 2) (64). Even
in the absence of reocclusion, the recovery of regional ven-
tricular function was precluded if the minimal diameter of
the lumen was less than 0.4 mm (Fig. 3) (44).
Because reflew occurs across a significant residual ste-
nosis in most patients (61), thrombolysis is not strictly com-
parable with experimental studies of reperfusion in which
the coronary occlusion was completely released. Instead,
clinical thrombolysis is better resembledby an experimental
model in which reflow is restricted to control levels and
lACC Vol. 9. No.4
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myocardium (41). In clinical studies of thrombolytic ther-
apy, patients who were treated by reperfusion early after
the onset of symptoms of infarction had a significantly greater
improvement in ventricular function. Schroder et al. (72)
found a correlation between infarct size measured from the
circumferential extent of hypokinesia and the time to treat-
TIME TO THROMBOLYTIC THERRPY, HRS.
Figure S. Relation between time from symptom onset to throm-
bolytic therapy andseverity of residual hypokinesia in the infarct
region (measured using thecenterline method andexpressed inSD
from normal) at follow-up. Motion in the infarct region was sig-
nificantly more hypokinetic in patients treated later than 2 hours
after symptom onset. (Reproduced with permission from Mathey
DG, et al. [78].)
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reactive hyperemia is prevented. Studies in such a model
have demonstrated shunting of coronary blood flow to the
subepicardium and persistent ischemia in the subendocar-
dium (65). This may prevent or delay recoveryof ventricular
function (66). On the other hand, when postischemic myo-
cardium is subjected to hyperperfusion at levels exceeding
normal coronary flow it regains much of its function (67).
Comparison with angioplasty. In concurrence with these
experimental findings, recent studies indicate that by itself
thrombolytic therapy results in less functional recovery than
does combined therapy with percutaneous angioplasty (68,69)
or acute revascularization with angioplasty alone (70,71).
Although some of these are preliminary reports, the obser-
vations suggest that reducing the residual stenosis by me-
chanical means salvages more myocardium than does re-
perfusion by thrombolytic therapy alone.
Partial reperfusion and survival. These studies of ven-
tricular function are paralleled by the Western Washington
trial (46) of survival after intracoronary streptokinase ther-
apy; the adequacy of reperfusion, defined angiographically
as complete, partial or no reperfusion, correlated signifi-
cantly with I year survival after acute myocardial infarction
(Fig. 4). The fact that survival in patients with partial re-
perfusion was nearly as poor as that of patients without
reperfusion indicates that angiographically apparent slow
anterograde flow or delayed washout of contrast medium is
a marker of inadequate reperfusion.
Time Is an Important Determinant of
Successful Outcome
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Experimental studies have clearly demonstrated that in-
farction progresses through the myocardial wall from sub-
endocardium to subepicardium with increasing duration of
coronary artery occlusion (19), and that reperfusion must
take place within 2 to 3 hours after occlusion to salvage
Figure 6. The effectiveness of intravenous streptokinase in re-
ducing hospital mortality after acute myocardial infarction. Pa-
tients are classified bytime from symptom onset to randomization.
Patients treated within I hour are included among those treated
:5:3 hours from symptom onset. (Adapted with permission from
GISSI [771.)
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Figure4. One year survival curves forthe63patients with anterior
infarction who received streptokinase, grouped according to re-
perfusion status. Patients with an angiographically normal coro-
nary flow rate survived better than those without reperfusion or
with perceptibly slow flow in the infarct artery. (Reproduced with
permission from Kennedy JW, et al. [46].)
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ment with intravenous streptokinase. Schwartz et al. (73)
observed that the infarct size measured from peak CK ac-
tivity was smaller and the ejection fraction at follow-up was
higher in patients whose coronary arteries were reperfused
<4 hours versus >4 hours after symptom onset. Mathey et
al. (74,75) found that improvement in wall motion at the
infarct site was significantlygreater if reperfusion was achieved
<2 '12 hours after symptom onset (Fig. 5), or if thrombolytic
therapy using either intracoronary streptokinase or intra-
venous urokinase was begun <2 hours after symptom onset,
compared with later reperfusion or treatment. Serruys et al.
(37) reported significantly greater recovery of regional wall
motion in patients treated with intracoronary or intravenous
streptokinase within 3 hours after symptom onset than in
those treated later. Few or no patients treated <2 hours after
symptom onset were enrolled in studies that failed to dem-
onstrate a significant relation between time to treatment and
left ventricular function (24,59,76).
The importance of early treatment was confirmed in the
recently completed Italian large scale controlled study of
intravenous streptokinase (77). Not only was significant re-
duction in in-hospital mortality limited to patients treated
early «6 hours) after symptom onset, but the magnitude
and significance of the reduction increased with progres-
sively earlier treatment (Fig. 6).
Conclusions. The evaluation of thrombolytic therapy
has been a three stage process. First, the success with which
the various thrombolytic agents achieved sustained reper-
fusion was determined. Because the underlying hypothesis
attributes enhanced survival to salvage of left ventricular
function, ventricular function was the second end point mea-
sured in studies of thrombolytic therapy. The final stage is
demonstration that thrombolysis improves survival after acute
myocardial infarction.
The recent decline in postinfarction mortality, however,
has made assessment of this end point more difficult and
expensive by necessitating enrollment and treatment of
hundreds or even thousands of patients in clinical trials
seeking to demonstrate a significant benefit of treatment on
survival. This has focused attention on using nonfatal end
points such as ventricular function. Measurements of re-
gional ventricular function in the infarct site are sensitive
indicators of the perfusion status of the infarct artery and
the degree of myocardial salvage. The use of quantitative
methods has facilitated analysis of the factors that influence
recovery of ventricular function after thrombolysis and en-
abled the demonstration of significant correlations even in
small study populations.
The selection of left ventricular function as the end point
has proved to be particularly appropriate for assessing the
value of thrombolytic therapy. Studies of reperfusion as a
means of salvaging jeopardized myocardium have been
characterized by a strong concordance between the exper-
imental studies of the effect of reperfusion on ventricular
function and infarct size, clinical studies measuring the ef-
fect of reperfusion on left ventricular function and clinical
trials testing the effect of thrombolytic therapy on survival.
Just as seen after reperfusion in the dog, thrombolytic ther-
apy in humans results in recovery of ventricular function if
I) reperfusion is adequate, and 2) if reperfusion is achieved
in the early hours after the onset of acute infarction. Under
these conditions, even patients with severe acute dysfunc-
tion may benefit. The same factors also determine the ef-
ficacy of thrombolytic therapy in reducing mortality. These
results provide indirect confirmation for the hypothesis that
enhancement of survival in patients treated with thrombol-
ytic agents is mediated by recovery of ventricular function.
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